Nanna Acquisition Gives Astellas Mitochondrial Expertise
Pays Up To $86m For Platform And R&D
Japanese firm pays cash plus milestones for UK specialist as it looks to integrate novel screening platform and gain know-how in mitochondrial modulators with potential applications.
You may also be interested in...
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.